Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response

Blood

Volumn 107, Issue 9, 2006, Pages 3787-3794

  Chorny, Alejo ^b   Gonzalez Rey, Elena ^b   Fernandez Martin, Amelia ^b   Ganea, Doina ^b   Delgado, Mario ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; CYTOTOXICITY; DENDRITIC CELL; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOTYPE; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 33645916180     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-4495     Document Type: Article

References (30)

1. Wagner JE, Donnenberg AD, Noga SJ, et al. Lymphocyte depletion of donor bone marrow by counterblow centrifugal elutriation: results of a phase I clinical trial. Blood. 1988;72:1168-1176.
2. Drobyski WT, Majewski D. Treatment of donor mice with an alpha beta T cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and efficiently prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. Blood. 1996;87:5355-5369.
3. Cooke KR, Krenger W, Hill G, et al. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood. 1998;92:2571-2580.
4. + lymphocytes in the marrow graft. Bone Marrow Transplant. 1999;23:443-450.
5. Banchereau J, Briere F, Caux, C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
6. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;109:685-711.
7. Rutella S, Lemoli RM. Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol Lett. 2004;94:11-26.
8. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769-779.
9. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med. 2001;193:F5-F9.
10. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev. 2003;196:125-146.
11. Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity. 2003;18:367-379.
12. Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood. 2003;101:3581-3589.
13. Pozo D, Delgado M. The many faces of vasoactive intestinal peptide in neuroimmunology: a cytokine rather a neuropeptide? FASEB J. 2004;18:1325-1334.
14. Delgado M., Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004;56:249-290.
15. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA. 2005;102:13562-13567.
16. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood. 2006;107:3632-3638.
17. Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol. 2005;175:7311-7324.
18. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003;18:605-617.
19. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity. 2003;18:155-167.
20. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
21. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303-310.
22. + regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295-302.
23. + regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295-302.
24. Gregg RK, Jain R, Schoenleber SJ, et al. A sudden decline in active membrane-bound TGF-beta impairs both T regulatory cell function and protection against autoimmune diabetes. J Immunol. 2004;173:7308-7316.
25. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1150.
26. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112:1688-1696.
27. + T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transpl. 2003;9:243-256.
28. + cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood. 2004;103:3970-3978.
29. Litvinova E, Maury S, Boyer O, et al. Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. Blood. 2002;100:2020-2025.
30. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol. 2004;4:24-34.